Peralta factual extract · Jazz Pharmaceuticals

2026 Q3 product sales, USD millions; SEC 10-Q filed 2026-11-02, Note 12 / p28

Xywav, nine months ended 2026-09-30: 1,362.2; 2025: 1,191.5

Epidiolex/Epidyolex, nine months ended 2026-09-30: 837.3; 2025: 772.0

Oncology total, nine months ended 2026-09-30: 1,082.8; 2025: 791.9

Total revenues, nine months ended 2026-09-30: 3,520.2; 2025: 3,069.6

Xywav, Q3 2026: 482.8; Q3 2025: 431.4

Zepzelca, Q3 2026: 104.4; Q3 2025: 79.3

Modeyso, Q3 2026: 61.1; Q3 2025: 11.0

Ziihera, Q3 2026: 20.6; Q3 2025: 8.3

2026 revenue guidance at 2026-11-02: 4,775 to 4,850

Peralta factual extract · Jazz Pharmaceuticals

2026 Q3 balance and claims, USD millions; SEC 10-Q pp7, 20-25

Cash and equivalents at 2026-09-30: 2,036.4

Current investments at 2026-09-30: 820.0

Current debt carrying amount at 2026-09-30: 1,017.3

Long-term debt carrying amount at 2026-09-30: 4,552.1

Debt principal at 2026-09-30: approximately 5,600.0

2030 convertible notes principal: 1,000.0; initial conversion price: about 153.05/share

2032 convertible notes principal: 1,300.0; conversion price: about 355.24/share

2030 notes principal must be cash settled; conversion spread can be cash or shares

Ordinary shares at 2026-09-30: 64.1 million; 2026 diluted guidance: 69 to 70 million

Actio acquisition closed 2026-09-15: 820.0 upfront net cash; up to 500.0 milestones

Peralta factual extract · Jazz Pharmaceuticals

Cash and financing, USD millions; SEC 2025 10-K F-8 and 2026 Q3 10-Q p12

Operating cash flow FY2025: 1,355.8; FY2024: 1,395.9; FY2023: 1,092.0

Operating cash flow nine months 2026: 1,330.0; nine months 2025: 993.3

Capital expenditure FY2025: 58.8; FY2024: 38.1; FY2023: 24.0

Capital expenditure nine months 2026: 54.0; nine months 2025: 42.0

Asset acquisition cash FY2025: 858.1; nine months 2026: 830.8

Acquired IPR&D investing cash FY2025: 42.5; nine months 2026: 77.0

Share-based compensation FY2025: 291.1; nine months 2026: 225.0

Share repurchases FY2025: 125.0; nine months 2026: 225.0

Acquired IPR&D expense Q3 2026: 754.2, mostly Actio accounting

Peralta factual extract · Jazz Pharmaceuticals

Ownership and market observations, dated sources

BlackRock beneficial shares: 5,872,123 or 9.3%, May 25 2026 proxy

Bruce C. Cozadd beneficial shares: 773,799 or 1.2%, May 25 2026 proxy

JAZZ Nasdaq regular-session close 2026-11-25: USD 245.29, Stock Analysis/Yahoo

USD/CAD Bank of Canada daily average 2026-11-25: 1.4219

XIC TSX regular-session close 2026-11-25: CAD 54.63, Stock Analysis/Yahoo